Datapoint: FDA Approves Host of Vyvanse Generics

As the nationwide Adderall shortage continues, the FDA last week approved the first generic versions of Takeda’s blockbuster ADHD drug Vyvanse (lisdexamfetamine dimesylate). Manufacturers of the newly approved generics include Actavis, Mylan, Sun Pharmaceutical and Teva. For the treatment of ADHD, Vyvanse holds covered or better status for 88% of all insured lives under the pharmacy benefit. About 43% of lives have preferred access to Vyvanse without utilization management restrictions.

SOURCE: MMIT Analytics, as of 8/31/23

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 28

Datapoint: North Carolina Medicaid Expansion Set for Dec. 1

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 27

Datapoint: New Mexico Orders Payers to Expand Behavioral Health Access

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 26

Datapoint: CMS Reinstates Medicaid Coverage for 500,000 People

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today